Education
About Us
Working with TipRanks
Follow Us
Qiagen NV (QGEN)
NYSE:QGEN
QGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.63 - $49.30
Previous CloseN/A
Volume260.87K
Average Volume (3M)1.11M
Market Cap
$8.72B
Enterprise Value$10.35B
Total Cash (Recent Filing)$794.77M
Total Debt (Recent Filing)$950.20M
Price to Earnings (P/E)108.7
Beta0.69
Next Earnings
May 05, 2025EPS Estimate
0.49Last Dividend Ex-Date
Jan 29, 2025Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding216,116,100
10 Day Avg. Volume1,048,869
30 Day Avg. Volume1,105,927
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.34
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap1.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.81
Enterprise Value/Ebitda28.65
Forecast
1Y Price Target
$48.68Price Target Upside27.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
---
Qiagen News
PremiumCompany Announcements
Qiagen Announces Voting Rights Update with Bank of America
PremiumCompany Announcements
QIAGEN N.V. Files 2024 Annual Report with SEC
PremiumCompany Announcements
Qiagen Manager Pledges Shares in Securities Lending Transaction
PremiumCompany Announcements
QIAGEN Announces Managerial Stock TransactionPremiumCompany Announcements
QIAGEN Announces Managerial Stock Unit Transactions
PremiumCompany Announcements
Qiagen Announces Managerial Stock Unit Grant---
Bulls Say, Bears Say
Bulls Say
Capital AllocationThe intent to return ~$300mn in shareholder capital is seen as a disciplined and shareholder-friendly capital allocation strategy by QIAGEN.
Financial PerformanceQiagen reported a slight beat on the top and bottom lines, and expects DD growth in QuantiFERON to persist through FY25 despite oft-mentioned concerns over competitive pressures.
Operational StrategyManagement expressed confidence in the ability to grow operating margins past 30%, aided by operational initiatives and the wind-down of NeuMoDx.
Bears Say
Competitive PressureThere is an expectation of more headline risk of competition from competitors in latent TB testing.
Market SentimentNear-term sentiment for QDI is softer, with sales tracking below long-range plans due to overall biopharma weakness and the SaaS transition.
Revenue ConcentrationQiagen's TB test (QFT) will see its third year of growth deceleration, signalling a normalization of testing demand.
---
Ownership Overview
0.54% Insiders
13.48% Mutual Funds
0.07% Other Institutional Investors
68.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QGEN FAQ
What was Qiagen NV’s price range in the past 12 months?
Qiagen NV lowest stock price was $37.63 and its highest was $49.30 in the past 12 months.
What is Qiagen NV’s market cap?
Qiagen NV’s market cap is $8.72B.
When is Qiagen NV’s upcoming earnings report date?
Qiagen NV’s upcoming earnings report date is May 05, 2025 which is in 30 days.
How were Qiagen NV’s earnings last quarter?
Qiagen NV released its earnings results on Feb 05, 2025. The company reported $0.61 earnings per share for the quarter, missing the consensus estimate of $0.616 by -$0.006.
Is Qiagen NV overvalued?
According to Wall Street analysts Qiagen NV’s price is currently Undervalued.
Does Qiagen NV pay dividends?
Qiagen NV pays a Annually dividend of $1.259 which represents an annual dividend yield of N/A. See more information on Qiagen NV dividends here
What is Qiagen NV’s EPS estimate?
Qiagen NV’s EPS estimate is 0.49.
How many shares outstanding does Qiagen NV have?
Qiagen NV has 216,116,100 shares outstanding.
What happened to Qiagen NV’s price movement after its last earnings report?
Qiagen NV reported an EPS of $0.61 in its last earnings report, missing expectations of $0.616. Following the earnings report the stock price went down -3.105%.
Which hedge fund is a major shareholder of Qiagen NV?
Currently, no hedge funds are holding shares in QGEN
---
Qiagen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$48.68 (27.23% Upside)
$48.68 (27.23% Upside)
Blogger Sentiment
Bullish
QGEN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 9.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.66%
12-Months-Change
Fundamentals
Return on Equity
2.27%
Trailing 12-Months
Asset Growth
-6.96%
Trailing 12-Months
Company Description
Qiagen NV
Qiagen N.V. is a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from biological samples. Operating in the life sciences and molecular diagnostics sectors, Qiagen offers a comprehensive portfolio of products and services, including sample technologies, assay technologies, bioinformatics, and automation systems. These products are utilized in academic research, pharmaceutical and biotechnology industries, forensics, and clinical diagnostics to advance scientific research and improve patient outcomes.
---
QGEN Company Deck
---
QGEN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Qiagen N.V. delivered a strong performance in Q4 2024, exceeding expectations in net sales and adjusted earnings, with significant growth in key product segments and improved profitability. However, challenges remain in specific regions and market segments, with cautious market conditions and declines in certain areas such as the Asia Pacific Japan region and Sample Technologies. Overall, the achievements and growth initiatives position the company well for future growth, despite current challenges.Read More>---
QGEN Stock 12 Month Forecast
Average Price Target
$48.68
▲(27.23% Upside)
Technical Analysis
Best Analysts Covering QGEN
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+8.09%
reiterated a buy rating 10 days ago
Copying Tycho Peterson's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +8.09% per trade.
---